PGNYHealthcare · Healthcare PlansThe 12 Wall Street analysts covering Progyny, Inc. hold a median 12-month price target of $35 — +31.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 2 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Progyny, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (94): The business earns solid, repeatable profits on what it owns.
Revisions (51): Analysts have, on balance, been cutting their forecasts.
Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PGNY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +31.4% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2026 | JP Morgan | Maintains | Neutral | $27 → $30 |
| 20 Aug 2026 | Wells Fargo | Initiates | Overweight | $37 |
| 13 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 13 Aug 2026 | Truist Securities | Maintains | Buy | $33 → $36 |
| 12 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
| 12 Aug 2026 | Barclays | Maintains | Equal-Weight | $34 → $30 |
| 28 July 2026 | Barclays | Downgrade | Equal-Weight | $27 → $34 |
| 28 July 2026 | Barclays | Downgrade | Equal-Weight | — |
| 24 July 2026 | BTIG | Maintains | Buy | $30 → $40 |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $30 → $36 |
| 13 July 2026 | Keybanc | Maintains | Overweight | — |
| 13 July 2026 | Keybanc | Maintains | Overweight | $30 → $35 |
| 22 June 2026 | Truist Securities | Maintains | Buy | — |
| 2 June 2026 | B of A Securities | Maintains | Buy | — |
| 19 May 2026 | Canaccord Genuity | Upgrade | Buy | — |
| 18 May 2026 | Barclays | Maintains | Overweight | — |
| 11 May 2026 | Citizens | Maintains | Market Outperform | — |
| 11 May 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PGNY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Progyny, Inc. returned +13.1% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 60% of US stocks
Cheaper than 24% of US stocks
Cheaper than 25% of US stocks
Higher than 40% of US stocks
Higher than 78% of US stocks
Higher than 29% of US stocks
Higher than 66% of US stocks
Higher than 62% of US stocks
Higher than 76% of US stocks
Higher than 92% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Progyny, Inc. has a market value of $2.0B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 5.3% year on year.
Net income over the same four quarters: $78.6M, a 6.0% net margin.
Diluted earnings per share, trailing twelve months: $0.92.
Free cash flow in the twelve months to 30 June 2026: $178.4M.
Progyny, Inc. spent $230.3M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 27.9×; forward P/E: 11.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Progyny, Inc. employs 835 people — $1.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| PGNYProgyny, Inc. | $2.0B | 97 |
| CLOVClover Health Investments Corp. | $2.2B | 67 |
| ALHCAlignment Healthcare, Inc. | $2.8B | 65 |
| OSCROscar Health, Inc. | $9.0B | 85 |
| MOHMolina Healthcare, Inc. | $10.4B | 33 |
| CNCCentene Corp. | $33.1B | 94 |
| BFLYButterfly Network, Inc.* | $2.1B | 73 |
* Nearest Healthcare names by size — few healthcare plans companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Progyny, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Progyny, Inc. announced that its Chief Financial Officer, Mark Livingston, will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 8, 2026, at 11:00 a.m. ET.
Why it matters — PGNY watchers would care because the presentation offers an opportunity for the company's CFO to communicate with investors and industry participants at a notable healthcare conference.
Zacks Investment Research highlighted Progyny, Inc. (PGNY) as one of four top-performing liquid stocks, alongside MNDY, MTCH, and WK, noting the companies' strong liquidity, growth attributes, and operational efficiency.
Why it matters — PGNY watchers would care because the company has been singled out by a research outlet as a top liquid stock with strong growth and operational efficiency, reflecting a favorable view of its fundamentals.
Progyny CEO Pete Anevski said the company expects member engagement and utilization to rebound after a more pronounced summer seasonal slowdown. Early renewal and new-client commitments have increased management's confidence in its outlook for the remainder of the year.
Why it matters — PGNY watchers would care because an expected utilization rebound and early client commitments suggest stronger near-term business momentum for the fertility-benefits provider.
Zacks Investment Research named Progyny, Inc. (PGNY) among four top-ranked liquid stocks, alongside IVZ, HUBS and HNGE, citing strong liquidity, growth attributes and operational efficiency for each.
Why it matters — A PGNY watcher would care because the company was singled out by Zacks as one of the top liquid stocks with strong growth and operational efficiency, which could raise its visibility among investors.
Progyny's second-quarter sales and adjusted earnings per share grew by 5% and 15%, respectively, but the stock fell after management issued conservative guidance for 7%–11% revenue growth in the third quarter. The stock later recovered some of its losses over the course of the trading day.
Why it matters — The market's reaction to management's cautious Q3 revenue forecast, despite solid quarterly results, highlights how sensitive Progyny's valuation is to forward-looking guidance.
The 12 Wall Street analysts covering Progyny, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Progyny, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Progyny, Inc. 97 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Progyny, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +31.4% from the last close, and Ticker Nerd's factor model ranks Progyny, Inc. 97 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Progyny, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.
Progyny, Inc. returned +13.1% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Progyny Inc is a healthcare benefits management company that provides fertility, family-building, and women’s health solutions for employers. Progyny designs integrated benefit programs that combine clinical expertise, personalized member support, selective provider networks, and pharmacy benefits to help organizations offer specialized reproductive and lifecycle care.
The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Progyny, Inc. to Present at the Wells Fargo Healthcare Conference". Progyny, Inc. announced that its Chief Financial Officer, Mark Livingston, will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 8, 2026, at 11:00 a.m. ET.
Progyny Inc is a healthcare benefits management company that provides fertility, family-building, and women’s health solutions for employers. Progyny designs integrated benefit programs that combine clinical expertise, personalized member support, selective provider networks, and pharmacy benefits to help organizations offer specialized reproductive and lifecycle care. Its services support areas such as fertility treatment, pregnancy and postpartum care, menopause and midlife support, and benefit navigation for adoption and surrogacy reimbursement. Progyny serves employers across multiple industries that want to include comprehensive family-building and women’s health coverage in their employee benefits packages. The company operates as a focused specialist in employer-sponsored healthcare benefits, playing a distinct role in making complex care pathways easier to manage for members, providers, and benefits administrators.
CEO Mr. Peter Anevski CPA · 835 employees · United States · https://www.progyny.com
